Single-molecule array assay reveals the prognostic impact of plasma LRIG1 in ovarian carcinoma

References

• Wild CP, Weiderpass E, Stewart B, editors. World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer; 2020. Available from http://publications.iarc.fr/586. Licence: CC BY-NC-ND 3.0 IGO.
   Google Scholar
• Willis S, Villalobos VM, Gevaert O, et al. Single gene prognostic biomarkers in ovarian cancer: a meta-analysis. PLoS One. 2016;11(2):e0149183.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Menon U, Gentry-Maharaj A, Burnell M, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial. Lancet 2021;397(10290):2182–2193.
   PubMed Web of Science ®Google Scholar
• Lycke M, Kristjansdottir B, Sundfeldt K. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol Oncol. 2018;151(1):159–165.
   PubMed Web of Science ®Google Scholar
• Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112(1):40–46.
   PubMed Web of Science ®Google Scholar
• Pokhriyal R, Hariprasad R, Kumar L, et al. Chemotherapy resistance in advanced ovarian cancer patients. Biomark Cancer. 2019;11:1179299X19860815.
   PubMedGoogle Scholar
• Feng L, Yan B, Huang Y, et al. Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer. Clin Epigenetics. 2021;13(1):141.
   PubMed Web of Science ®Google Scholar
• Guo D, Holmlund C, Henriksson R, et al. The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in ascidiacea. Genomics 2004;84(1):157–165.
   PubMed Web of Science ®Google Scholar
• Powell AE, Wang Y, Li Y, et al. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell 2012;149(1):146–158.
   PubMed Web of Science ®Google Scholar
• Mao F, Holmlund C, Faraz M, et al. Lrig1 is a haploinsufficient tumor suppressor gene in malignant glioma. Oncogenesis 2018;7(2):13.
   PubMedGoogle Scholar
• Neirinckx V, Hedman H, Niclou SP. Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases for cancer therapy. Biochim Biophys Acta Rev Cancer. 2017;1868(1):109–116.
   PubMed Web of Science ®Google Scholar
• Gumienny TL, MacNeil L, Zimmerman CM, et al. Caenorhabditis elegans SMA-10/LRIG Is a conserved transmembrane protein that enhances bone morphogenetic protein signaling. PLoS Genet. 2010;6(5):e1000963.
   PubMed Web of Science ®Google Scholar
• Herdenberg C, Mutie PM, Billing O, et al. LRIG proteins regulate lipid metabolism via BMP signaling and affect the risk of type 2 diabetes. Commun Biol. 2021;4(1):90.
   PubMed Web of Science ®Google Scholar
• Yi W, Holmlund C, Nilsson J, et al. Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1. Exp Cell Res. 2011;317(4):504–512.
   PubMed Web of Science ®Google Scholar
• Partheen K, Kristjansdottir B, Sundfeldt K. Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol. 2011;22(4):244–252.
   PubMed Web of Science ®Google Scholar
• Shih IM, Kurman RJ. A proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164(5):1511–1518.
   PubMed Web of Science ®Google Scholar
• Rissin D, Kan C, Campbell T, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010;28(6):595–599.
   PubMed Web of Science ®Google Scholar
• The Human Protein Atlas, version 21.0. 2021 [accessed 2021 Nov 15]. https://www.proteinatlas.org
   Google Scholar
• Kim JM, Joung KH, Lee JC, et al. Soluble LRIG2 is a potential biomarker for type 2 diabetes mellitus. Ann Transl Med. 2021;9(21):1612–1620.
   PubMed Web of Science ®Google Scholar
• Deutsch EW, Lam H, Aebersold R. PeptideAtlas: a resource for target selection for emerging targeted proteomics workflows. EMBO Rep. 2008;9(5):429–434.
   PubMed Web of Science ®Google Scholar
• Tanemura A, Nagasawa T, Inui S, et al. LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol Surg. 2005;31(4):423–430. PMID: 15871317
   PubMed Web of Science ®Google Scholar
• Lindström AK, Ekman K, Stendahl U, et al. LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. Int J Gynecol Cancer. 2008;18(2):312–317.
   PubMed Web of Science ®Google Scholar
• Krig SR, Frietze S, Simion C, et al. Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERα-positive breast cancer. Mol Cancer Res. 2011;9(10):1406–1417.
   PubMed Web of Science ®Google Scholar
• Muller S, Lindquist D, Kanter L, et al. Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma. Int J Oncol. 2013;42(1):247–252.
   PubMed Web of Science ®Google Scholar
• Sheu JJ, Lee CH, Ko JY, et al. Chromosome 3p12.3-p14.2 and 3q26.2-q26.32 are genomic markers for prognosis of advanced nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2009;18(10):2709–2716.
   PubMed Web of Science ®Google Scholar
• Lindquist D, Näsman A, Tarján M, et al. Expression of LRIG1 is associated with good prognosis and human papillomavirus status in oropharyngeal cancer. Br J Cancer. 2014;110(7):1793–1800.
   PubMed Web of Science ®Google Scholar
• Kvarnbrink S, Karlsson T, Edlund K, et al. LRIG1 is a prognostic biomarker in non-small cell lung cancer. Acta Oncol. 2015;54(8):1113–1119.
   PubMed Web of Science ®Google Scholar
• Yang B, Dai C, Tan R, et al. Lrig1 is a positive prognostic marker in hepatocellular carcinoma. Onco Targets Ther. 2016;9:7071–7079.
   PubMed Web of Science ®Google Scholar
• Stutz M, Shattuck D, Laederich M, et al. LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene 2008;27(43):5741–5752.
   PubMed Web of Science ®Google Scholar
• Wu X, Hedman H, Bergqvist M, et al. Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity. Acta Oncol. 2012;51(1):69–76.
   PubMed Web of Science ®Google Scholar
• Yang H, Yao J, Yin J, et al. Decreased LRIG1 in human ovarian cancer cell SKOV3 upregulates MRP-1 and contributes to the chemoresistance of VP16. Cancer Biother Radiopharm. 2016;31(4):125–132.
   PubMed Web of Science ®Google Scholar
• Morrison M, Williams M, Vaught D, et al. Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth. Oncogene 2016;35(9):1143–1152.
   PubMed Web of Science ®Google Scholar
• Billing O, Holmgren Y, Nosek D, et al. LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance. Oncogene 2021;40(21):3707–3718.
   PubMed Web of Science ®Google Scholar
• Hedman H, Henriksson R. LRIG inhibitors of growth factor signalling - double-edged swords in human cancer? Eur J Cancer. 2007;43(4):676–682.
   PubMed Web of Science ®Google Scholar
• Herrera B, van Dinther M, Ten Dijke P, et al. Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation. Cancer Res. 2009;69(24):9254–9262.
   PubMed Web of Science ®Google Scholar
• Peng J, Yoshioka Y, Mandai M, et al. The BMP signaling pathway leads to enhanced proliferation in serous ovarian cancer—A potential therapeutic target. Mol Carcinog. 2016;55(4):335–345.
   PubMed Web of Science ®Google Scholar
• Coffman LG, Choi YJ, McLean K, et al. Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop. Oncotarget 2016;7(6):6916–6932.
   PubMedGoogle Scholar
• Fukuda T, Fukuda R, Tanabe R, et al. BMP signaling is a therapeutic target in ovarian cancer. Cell Death Discov. 2020;6(1):139.
   PubMed Web of Science ®Google Scholar
• Sun W, Duan T, Ye P, et al. TSVdb: a web-tool for TCGA splicing variants analysis. BMC Genomics. 2018;19(1):405.
   PubMedGoogle Scholar